These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37523013)

  • 1. A Perspective on Model-Informed IVIVC for Development of Subcutaneous Injectables.
    Corpstein CD; Li T
    Pharm Res; 2023 Jul; 40(7):1633-1639. PubMed ID: 37523013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
    Somayaji MR; Das D; Przekwas A
    Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report.
    Suarez-Sharp S; Cohen M; Kesisoglou F; Abend A; Marroum P; Delvadia P; Kotzagiorgis E; Li M; Nordmark A; Bandi N; Sjögren E; Babiskin A; Heimbach T; Kijima S; Mandula H; Raines K; Seo P; Zhang X
    AAPS J; 2018 Aug; 20(6):93. PubMed ID: 30151612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional vs Mechanistic IVIVC: A Comparative Study in Establishing Dissolution Safe Space for Extended Release Formulations.
    Kollipara S; Ahmed T; Chougule M; Guntupalli C; Sivadasu P
    AAPS PharmSciTech; 2024 May; 25(5):118. PubMed ID: 38806735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiphysics Simulation of Local Transport and Absorption Coupled with Pharmacokinetic Modeling of Systemic Exposure of Subcutaneously Injected Drug Solution.
    Corpstein CD; Hou P; Park K; Li T
    Pharm Res; 2023 Dec; 40(12):2873-2886. PubMed ID: 37344601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulate SubQ: The Methods and the Media.
    Li D; Chow PY; Lin TP; Cheow C; Li Z; Wacker MG
    J Pharm Sci; 2023 Jun; 112(6):1492-1508. PubMed ID: 34728176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
    Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S
    J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an In Vitro System To Emulate an In Vivo Subcutaneous Environment: Small Molecule Drug Assessment.
    Lou H; Hageman MJ
    Mol Pharm; 2022 Nov; 19(11):4017-4025. PubMed ID: 36279508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards in vitro - In vivo correlation models for in situ forming drug implants.
    Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ
    J Control Release; 2024 Aug; 372():648-660. PubMed ID: 38936743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.
    Cardot JM; Lukas JC; Muniz P
    AAPS J; 2018 Aug; 20(6):95. PubMed ID: 30159772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications.
    Modi NB; Lam A; Lindemulder E; Wang B; Gupta SK
    Biopharm Drug Dispos; 2000 Nov; 21(8):321-6. PubMed ID: 11514951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
    Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
    Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions.
    Margolskee A; Darwich AS; Galetin A; Rostami-Hodjegan A; Aarons L
    AAPS J; 2016 Mar; 18(2):321-32. PubMed ID: 26667356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.